|
See related Cytarabine-Hospira inj information |
|
|
|
Manufacturer |
Hospira |
|
Distributor |
Hong Kong: Zuellig |
|
Contents |
Cytarabine |
|
Indications |
Induction & maintenance of remission in acute myeloid leukaemia of both adults & childn. Treatment of leukemias eg acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase) & erythroleukaemia. Non-Hodgkin's lymphoma. |
|
Dosage |
Monotherapy 200 mg/m2 daily by continuous IV infusion over 24 hr for 5 days every 2 wk. |
|
Contraindications |
Lactation. |
|
Special Precautions |
Should undergo close medical supervision including daily assessment of leucocyte & platelet, intrathecal use, impaired hepatic function, frequent assessments of blood uric levels should be made. Pregnancy. |
|
Adverse Drug Reactions |
Myelosuppression, nausea, vomiting, cytarabine (Ara: C) syndrome (fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis & malaise. Anorexia, diarrhoea, oral & anal inflammation or ulceration, fever, rash, thrombophlebitis, bleeding (all sites), hepatic dysfunction.
View ADR Monitoring Form |
|
Drug Interactions |
Methotrexate.
View more drug interactions with Cytarabine-Hospira |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01BC01 - cytarabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Cytarabine-Hospira injection |
|
Cytarabine-Hospira 1 g/10 mL x 1's |
|
Cytarabine-Hospira 2 g/20 mL x 1's |
|
|
|
Manufacturer: |
Hospira |
|
Distributor: |
Hong Kong: Zuellig
|
|
|
|
